Skip Nav Destination
Issues
15 August 2012
-
Cover Image
Cover Image
Fusions of the ROS1 kinase occur in about 1.5% of NSCLC cases. In a subset of these tumors, ROS1 fusion protein and mutant EGFR protein were found to be localized in the same area on serial sections, suggesting that coexpression of the two important therapeutic RTK targets can occur in NSCLC. Immunohistochemical staining of total EGFR protein is shown in a SLC34A2-ROS1 fusion positive NSCLC tumor. For details, see the article by Rimkunas and colleagues on page 4449 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Statistics in Clinical Cancer Research
Molecular Pathways
CCR Focus
Human Cancer Biology
The Zinc Finger Gene ZIC2 Has Features of an Oncogene and Its Overexpression Correlates Strongly with the Clinical Course of Epithelial Ovarian Cancer
Sergio Marchini; Elizabeth Poynor; Richard R. Barakat; Luca Clivio; Michela Cinquini; Robert Fruscio; Luca Porcu; Cecilia Bussani; Maurizio D’Incalci; Eugenio Erba; Michela Romano; Giorgio Cattoretti; Dionyssios Katsaros; Andrew Koff; Lucio Luzzatto
Cancer Therapy: Preclinical
Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy
François Kuonen; Julien Laurent; Chiara Secondini; Girieca Lorusso; Jean-Christophe Stehle; Thierry Rausch; Eveline Faes-van't Hull; Grégory Bieler; Gian-Carlo Alghisi; Reto Schwendener; Snezana Andrejevic-Blant; René-Olivier Mirimanoff; Curzio Rüegg
Improved Statistical Modeling of Tumor Growth and Treatment Effect in Preclinical Animal Studies with Highly Heterogeneous Responses In Vivo
Teemu D. Laajala; Jukka Corander; Niina M. Saarinen; Katja Mäkelä; Saija Savolainen; Mari I. Suominen; Esa Alhoniemi; Sari Mäkelä; Matti Poutanen; Tero Aittokallio
Imaging, Diagnosis, Prognosis
Cancer Therapy: Clinical
The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations
Stephanie Heon; Beow Y. Yeap; Neal I. Lindeman; Victoria A. Joshi; Mohit Butaney; Gregory J. Britt; Daniel B. Costa; Michael S. Rabin; David M. Jackman; Bruce E. Johnson
Predictive Biomarkers and Personalized Medicine
Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel
Anne-Joy M. de Graan; Cynthia S. Lancaster; Amanda Obaidat; Bruno Hagenbuch; Laure Elens; Lena E. Friberg; Peter de Bruijn; Shuiying Hu; Alice A. Gibson; Gitte H. Bruun; Thomas J. Corydon; Torben S. Mikkelsen; Aisha L. Walker; Guoqing Du; Walter J. Loos; Ron H. N. van Schaik; Sharyn D. Baker; Ron H. J. Mathijssen; Alex Sparreboom
Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy
Luis J. Leandro-García; Susanna Leskelä; Carlos Jara; Henrik Gréen; Elisabeth Åvall-Lundqvist; Heather E. Wheeler; M. Eileen Dolan; Lucia Inglada-Perez; Agnieszka Maliszewska; Aguirre A. de Cubas; Iñaki Comino-Méndez; Veronika Mancikova; Alberto Cascón; Mercedes Robledo; Cristina Rodríguez-Antona
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
Philippe A. Cassier; Elena Fumagalli; Piotr Rutkowski; Patrick Schöffski; Martine Van Glabbeke; Maria Debiec-Rychter; Jean-François Emile; Florence Duffaud; Javier Martin-Broto; Bruno Landi; Antoine Adenis; François Bertucci; Emmanuelle Bompas; Olivier Bouché; Serge Leyvraz; Ian Judson; Jaap Verweij; Paolo Casali; Jean-Yves Blay; Peter Hohenberger; for the European Organisation for Research and Treatment of Cancer
A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
Stephen K. Chia; Vivien H. Bramwell; Dongsheng Tu; Lois E. Shepherd; Shan Jiang; Tammi Vickery; Elaine Mardis; Samuel Leung; Karen Ung; Kathleen I. Pritchard; Joel S. Parker; Philip S. Bernard; Charles M. Perou; Matthew J. Ellis; Torsten O. Nielsen
Letters to the Editor
Correction
Advertisement